Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TiNK and Isatuximab in Relapsed/Refractory Multiple Myeloma
NCT06203912Phase 1Completed
- Start
- Mar 2024
- Primary completion
- May 2026
- Modality
- Antibody Conjugates, Lymphokine-Activated Killer Cells, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of transforming growth factor-beta-imprinted natural killer cells in multiple myeloma (MM). Primary endpoint: Incidence and severity of adverse events. Started Mar 2024; status: completed.
02
Drugs
transforming growth factor-beta-imprinted natural killer cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06203912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06203912.